Type 2 diabetes mellitus is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action. Type 2 diabetes can initially be treated with oral agent monotherapy, but due to the progressive nature of this disorder, patients eventually require the addition of other oral agents, often as a prelude to insulin therapy. Several new approaches are developed to improve glycemic control with minimum side effects.